Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Radiotherapy sensitizes unresponsive tumors to the antineoplastic activity of antibodies that target the inhibitory receptor CTLA-4 on T cells. One molecular mechanism accounting for this therapeutic synergy is the induction of NKG2D ligands on irradiated tumor cells. The fact that NKG2D receptors must be engaged for the elicitation of CD8(+) T-cell antitumor responses has important clinical implications.

Original publication

DOI

10.4161/onci.23127

Type

Journal article

Journal

Oncoimmunology

Publication Date

03/2013

Volume

2

Addresses

Department of Pathology; New York University School of Medicine; New York, NY USA ; Department of Radiation Oncology; New York University School of Medicine; New York, NY USA.